$PMT

PennyMac Mortgage Investment Trust Reports Second Quarter 2026 Results

PennyMac Mortgage Investment Trust (PMT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 PennyMac Mortgage Investment Trust Reports Second Quarter 2026 Results WESTLAKE VILLAGE, Calif. – July 29, 2026 – PennyMac Mortgage Investment Trust (NYSE: PMT) today reported net income attributable to common shareholders of $20 million, or $0.23 per common share on

Original reporting
Published Jul 29, 2026, 8:43 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 29, 2026, 8:46 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$PMT
Bullish
medium confidence
Mentioned
$PMT
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$PMTBullishMed
01

Why it matters

The company disclosed a concrete MSR reduction path (agreement to sell $13B UPB of low-coupon Agency MSRs, expected close end of August) and a correspondent acquisition policy change, alongside 2Q26 segment performance.

02

Market read

Traders can update expectations for PMT’s earnings power and risk profile ahead of the end-of-August MSR sale close, using the disclosed segment metrics and portfolio actions.

03

What to watch

The filing emphasizes expected return potential but does not quantify execution risk, hedging impacts, or how quickly the redeployed capital will translate into earnings versus fair-value movements.

Relevance 7/10Novelty 7/10Timing: after-hours following 2Q26 results and MSR sale agreement disclosure, with expected MSR sale close end of August

Background

PennyMac Mortgage Investment Trust is a mortgage REIT with exposure to MSRs and credit-sensitive strategies (CRT/subordinate bonds) and interest-rate-sensitive strategies (MSRs and MBS).

Company-level read

Ticker impact

$PMTBullishMedium confidence
Context

PMT reported 2Q26 net income of $20M ($0.23/share) and said it will sell $13B UPB of MSRs and stop Agency-eligible correspondent acquisitions.

Expected impact

Near-term volatility possible as investors reprice MSR runoff and the timing/realization of the low-to-mid teens return redeployment plan.

Evidence & confidence

The filing discloses both quarterly results and specific portfolio actions (MSR sale agreement, acquisition policy change) plus segment metrics that show MSR fair value and income dynamics.

Market effects

Mortgage REITs and MSR-heavy strategies may see read-across on how quickly capital can be redeployed from MSRs into CRT/subordinate credit.

Limited direct regional impact; primarily US mortgage credit and securitization market plumbing.

Low global relevance; impacts are concentrated in US agency/non-agency mortgage securitization and MSR markets.

Counterpoint

The plan to reduce MSR exposure could pressure near-term earnings if MSR-related income/valuation effects are replaced by lower realized yields or slower deployment into the targeted credit opportunities.

Key entities

  • PennyMac Mortgage Investment Trust

    Reported 2Q26 results and outlined balance-sheet realignment to reduce MSR exposure and redeploy into credit investments.

Related articles

$BLCOHighAI 9/10

Why is Bausch + Lomb stock surging today?

Bausch + Lomb (BLCO) stock rose 7.3% after Q3 2026 earnings beat estimates, with adjusted EPS of $0.34 vs. $0.21 expected, and revenue of $1.375B, up 7% YoY. The company raised full-year guidance for the third time, citing growth across all segments and improved profitability. The stock reached a 52-week high of $19.09.

$GEHCHighAI 9/10

GE HealthCare Q3 2026 slides: margin gains fuel guidance raise

GE HealthCare (GEHC) reported Q3 2026 revenue of $5.5B, up 6.2%, and EPS of $1.34, up 25.1%. The company raised full-year guidance due to margin expansion and operational improvements. Shares rose 6.9% to $76.02. All segments showed growth, with Pharmaceutical Diagnostics leading at 13.8%. Free cash flow increased to $793M. Guidance updated for higher revenue, EPS, and free cash flow.

$STGWMed

Stagwell earnings loom as investors watch media business revival

Stagwell Inc. reports Q3 earnings with analysts expecting $0.31 EPS on $838.4M revenue, up 27% and 13% YoY. Wall Street is bullish, with a $10.71 avg. price target. The company's media business revival and recent acquisitions, like Freestar, are key focuses. Stagwell's stock is up over 100% from its 52-week low, with investors watching for sustained growth.

$OSWHighAI 8/10

Why is OneSpaWorld stock surging today?

OneSpaWorld (OSW) stock rose 11.3% after reporting record Q3 results, with EPS of $0.34 and revenue of $276.5M, both beating estimates. The company announced a $100M share buyback and a 25% dividend increase. Net income and adjusted EBITDA also hit records, but Q4 guidance was slightly below consensus.